NCT03712280View on ClinicalTrials.gov

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

July 14, 2020

Study Completion Date

July 14, 2020

Conditions
Hepatic CirrhosisHepatic Encephalopathy (HE)
Interventions
DRUG

MNK6106

1 gram tablet of MNK6106 for oral administration

DRUG

Rifaximin

550 mg tablet of rifaximin for oral administration

Trial Locations (5)

33702

Global Clinical Professionals, St. Petersburg

78215

American Research Corporation at the Texas Liver Institute, San Antonio

92118

Southern California Research Center, Coronado

92377

Inland Empire Clinical Trials, Rialto

00927

Fundacion de Investigacion (Research Foundation), San Juan

Sponsors

Lead Sponsor

Mallinckrodt
All Listed Sponsors
lead

Mallinckrodt

INDUSTRY

NCT03712280 - MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) | Biotech Hunter | Biotech Hunter